SEC Form 4 · accession 0001209191-16-102145
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas B Neff
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
Feb 22, 2016
Accepted (ET)
Feb 24, 2016 · 9:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 22, 2016 | S | 13,200 | $19.80 | D | 3,596,207 | D | |
| Common StockF1 | Feb 22, 2016 | S | 300 | $20.30 | D | 3,595,907 | D | |
| Common StockF3 | Feb 22, 2016 | A | 100,000 | $0.00 | A | 3,695,907 | D | |
| Common StockF1,F4 | Feb 23, 2016 | S | 10,800 | $18.21 | D | 3,685,107 | D | |
| Common StockF1,F5 | Feb 23, 2016 | S | 2,700 | $19.16 | D | 3,682,407 | D | |
| Common Stock | holding | — | — | — | 145,070 | I | By Family Partnership | |
| Common Stock | holding | — | — | — | 20,000 | I | By Spouse | |
| Common StockF6 | holding | — | — | — | 60,946 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $19.39 | Feb 22, 2016 | A | 165,000 | A | — | Feb 22, 2026 | Common Stock | 165,000 | 165,000 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices ranging from $19.30 to $20.26. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Represents the grant of restricted stock units that vest over time.
- F4The shares were sold at prices ranging from $17.93 to $18.88. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5The shares were sold at prices ranging from $18.94 to $19.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F6The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
- F7Twenty-five percent of the shares subject to the option vest on March 1, 2017, and the remainder vests in equal amounts quarterly thereafter for the following three years.